Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 10 clinical trials
Talazoparib in Advanced Breast Cancer Patients With Homologous Recombinant Deficiency

Talazoparib has shown clinical efficacy in breast cancer patients with germline BRCA1 or BRCA2 mutations. Beyond BRCA1 and BRCA2 mutations, it is plausible that talazoparib may have activity in patients with homologous recombination defects (HRD).

  • 0 views
  • 28 May, 2021
  • 1 location
Study of Olaparib in Metastatic Renal Cell Carcinoma Patients With DNA Repair Gene Mutations (ORCHID)

, BRCA1, BRCA2, PALB2, CHEK2, BRIP1, RAD51C, BARD1, CDK12, CHEK1, FANCL, PP2R2A, RAD51B, RAD51D, or RAD54L who have had prior treatment with at least one immune checkpoint inhibitor or anti-VEGF

palb2
platelet count
liver metastasis
vegf
BARD1
  • 21 views
  • 09 Feb, 2022
  • 1 location
Testing Olaparib in Patients With Advanced or Metastatic (Cancer That Has Spread) Bladder Cancer With DNA-Repair Genetic Changes

This phase II trial studies how well olaparib works in treating patients with urothelial cancer with deoxyribonucleic acid (DNA)-repair defects that has spread to other places in the body (advanced or metastatic) and usually cannot be cured or controlled with treatment. PARPs are proteins that help repair DNA mutations. PARP …

bladder cancer
metastasis
follicle stimulating hormone
avelumab
neutrophil count
  • 111 views
  • 20 Jun, 2022
  • 1 location
Phase II Trial of Talazoparib in BRCA1/2 Wild-type HER2-negative Breast Cancer and Other Solid Tumors

The aim of this single-arm phase 2 clinical trial is to evaluate the anti-cancer activity of Talazoparib (also known as BMN 673) in patients with advanced breast cancer with specific genetic or tumor genomic alterations. Patients with either triple-negative or HER2-negative breast cancer are eligible.

progesterone receptor
palb2
platelet count
talazoparib
her2-negative breast cancer
  • 5 views
  • 08 Sep, 2021
  • 1 location
Olaparib in Men With High-Risk Biochemically-Recurrent Prostate Cancer Following Radical Prostatectomy, With Integrated Biomarker Analysis

Olaparib has demonstrated preliminary efficacy in metastatic castration-resistant prostate cancer. In a trial of 49 evaluable patients treated with olaparib, 11 / 49 experienced a PSA response, and every patient with a radiographic response also had a PSA5 response. Ten of 11 responders had mutations in DNA repair genes. While …

platelet count
ct scan
androgens
metastatic disease
local therapy
  • 8 views
  • 23 Mar, 2022
  • 4 locations
Berzosertib and Irinotecan in Treating Patients With Progressive, Metastatic, or Unresectable TP53 Mutant Gastric or Gastroesophageal Junction Cancer

This phase II trial studies the how well berzosertib and irinotecan work in treating patients with gastric or gastroesophageal junction cancer that is growing, spreading or getting worse (progressive), has spread to other places in the body (metastatic), or cannot be removed by surgery (unresectable). Berzosertib may stop the growth …

  • 0 views
  • 16 Jun, 2022
  • 14 locations
Niraparib Plus Carboplatin in Patients With Homologous Recombination Deficient Advanced Solid Tumor Malignancies

This is a multi-institutional Phase I dose-escalation and dose-expansion trial for patients with advanced, solid tumor malignancies who have pre-identified deleterious germline or somatic mutations in the homologous recombination deoxyribonucleic acid (DNA) repair pathway (HR deficient). The trial is designed to assess the efficacy and safety of niraparib plus carboplatin …

aptt
carboplatin
solid tumour
neutrophil count
major surgery
  • 7 views
  • 09 Sep, 2021
  • 3 locations
Strategic Targeting for Optimal Prevention of Cancer (STOP-Cancer)

The primary goal of the study is to record data over the observation period to evaluate the clinical benefit of using hereditary cancer genomic diagnostics to assess overall hereditary genetic cancer risk profile and to help guide physicians to pursue preventative measures, which may lead to early detection and treatment …

  • 14 views
  • 09 Feb, 2022
  • 1 location
Homologous Recombination Deficiency Status in Epithelial Ovarian Cancer

testing of 36 genes would be given for these patients in their peripheral blood and tumor tissues. These 36 genes include: BRCA1, BRCA2, ABRAXAS1(FAM175A, ATM, ATR, BAP1, BARD1, BRIP1, C11ORF30EMSY

palb2
EPCAM
NBN
BARD1
CDH1
  • 0 views
  • 21 Feb, 2022
  • 1 location
An Intervention to Increase Genetic Testing in Families Who May Share a Gene Mutation Related to Cancer Risk

The purpose of this study is to evaluate a cascade genetic testing intervention. Cascade testing is the process of offering genetic testing to people who are at risk of having inherited a possibly harmful gene change that has been found in their family. This process is repeated as more people …

Accepts healthy volunteers
  • 0 views
  • 29 Jun, 2022
  • 5 locations